• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesTry Devex Pro
    • News
    • Global health

    How far are we from a licensed vaccine for deadly Marburg?

    Clinical trials for a vaccine candidate have started in Rwanda which is two weeks into the response for its first outbreak.

    By Sara Jerving // 10 October 2024

    Whenever a Marburg outbreak pops up it’s alarming — as it is a filovirus similar to Ebola with a mortality rate of up to 88%.

    But a key difference between Ebola and Marburg outbreaks is that the Zaire strain of Ebola has a licensed vaccine and approved treatments, whereas there's neither a licensed vaccine nor treatments approved for Marburg.

    Rwanda is nearly two weeks into its response, after reporting its first detection of the Marburg disease on Sept. 27, which had already spread to seven of the country’s 30 districts.

    This article is free to read - just register or sign in

    Access news, newsletters, events and more.

    Join usSign in

    More reading:

    ► New Marburg outbreak sparks race to test vaccines

    ► The pipeline for pandemic products is bare. Here's why it matters

    ► Pan-African platform aims to hasten clinical trials

    • Funding
    • Global Health
    • Innovation & ICT
    • Private Sector
    • Biomedical Advanced Research and Development Authority (BARDA)
    • Rwanda Biomedical Centre (RBC)
    • Sabin Vaccine Institute
    • International AIDS Vaccine Initiative (IAVI)
    • Rwanda
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • Sara Jerving

      Sara Jervingsarajerving

      Sara Jerving is a Senior Reporter at Devex, where she covers global health. Her work has appeared in The New York Times, the Los Angeles Times, The Wall Street Journal, VICE News, and Bloomberg News among others. Sara holds a master's degree from Columbia University Graduate School of Journalism where she was a Lorana Sullivan fellow. She was a finalist for One World Media's Digital Media Award in 2021; a finalist for the Livingston Award for Young Journalists in 2018; and she was part of a VICE News Tonight on HBO team that received an Emmy nomination in 2018. She received the Philip Greer Memorial Award from Columbia University Graduate School of Journalism in 2014.

    Search for articles

    Related Stories

    Sponsored by GSKInside the science shaping the next generation of malaria vaccines

    Inside the science shaping the next generation of malaria vaccines

    Global HealthGavi's board tasked with strategy shift in light of $3B funding gap

    Gavi's board tasked with strategy shift in light of $3B funding gap

    Global HealthUS aid cuts overshadow HIV research advances

    US aid cuts overshadow HIV research advances

    78th World Health AssemblyA new model for funding global health takes shape

    A new model for funding global health takes shape

    Most Read

    • 1
      Special edition: The many questions that remain after UNGA80
    • 2
      Trump's 'America First' global health plan sidelines NGOs
    • 3
      Save the Children US CEO details how they navigated the budget crash
    • 4
      How ex-USAID staffers turned crisis into action and mobilized $110M
    • 5
      Mark Green urges aid community to reengage as US resets assistance
    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement